Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
Neonc Technologies, Inc.
Jonsson Comprehensive Cancer Center
Iambic Therapeutics, Inc
Mayo Clinic
Dana-Farber Cancer Institute
UNC Lineberger Comprehensive Cancer Center
Virginia Commonwealth University
Washington University School of Medicine
Jonsson Comprehensive Cancer Center
Poitiers University Hospital
National Cancer Institute (NCI)
Apollomics Inc.
NRG Oncology
Columbia University
University of South Florida
Cedars-Sinai Medical Center
ABM Therapeutics Corporation
Dana-Farber Cancer Institute
Washington University School of Medicine
Wake Forest University Health Sciences
Mayo Clinic
Second Affiliated Hospital of Guangzhou Medical University
University of Southern California
National Cancer Institute (NCI)
Masonic Cancer Center, University of Minnesota
University of Florida
Kaohsiung Medical University Chung-Ho Memorial Hospital
Mayo Clinic
Quadriga Biosciences, Inc.
Health Clinics Limited
Albert Einstein College of Medicine
University Hospital Tuebingen
Chinese PLA General Hospital
Stanford University
IGF Oncology, LLC
Yale University
Maastricht Radiation Oncology
Masonic Cancer Center, University of Minnesota
National Institutes of Health Clinical Center (CC)
University of Utah
AHS Cancer Control Alberta
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
SWOG Cancer Research Network
National Cancer Institute (NCI)
Angiochem Inc
INSYS Therapeutics Inc
National Cancer Institute (NCI)